Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Diffuse large-cell lymphoma.

¹Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, IL, USA.

Annals of Oncology : Official Journal of the European Society for Medical Oncology

|March 9, 2000

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).

Annals of oncology : official journal of the European Society for Medical Oncology·2017

Same author

The role of body mass index in survival outcome for lymphoma patients: US intergroup experience.

Annals of oncology : official journal of the European Society for Medical Oncology·2014

Same author

A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213.

Annals of oncology : official journal of the European Society for Medical Oncology·2013

Same author

Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study.

Annals of oncology : official journal of the European Society for Medical Oncology·2009

Same author

Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study.

Annals of oncology : official journal of the European Society for Medical Oncology·2008

Same author

Stromal gene signatures in large-B-cell lymphomas.

The New England journal of medicine·2008

Same journal

HER2-directed TAC T cells in solid tumors: a step forward, but not yet a therapeutic leap.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Same journal

The ethical obligation to use positive trial results.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Same journal

Lorlatinib: The Crown Jewel of ALK Inhibitors.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Same journal

TROP2-Directed Antibody Drug Conjugates: New First-Line Treatment for All Patients with Advanced Triple-Negative Breast Cancer?

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Same journal

When artificial intelligence learns to abstain: towards clinically responsible diagnostic support in liver pathology.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Same journal

PRMT5 inhibitors in MTAP loss NSCLC with actionable genomic alterations: a new kid on the block?

Annals of oncology : official journal of the European Society for Medical Oncology·2026

See all related articles

New treatments are needed for diffuse large cell lymphoma. Research focuses on novel drugs, dose escalation, overcoming resistance, antibody combinations, and stem-cell support to improve patient outcomes.

Area of Science:

Hematology
Oncology
Clinical Trials

Background:

Diffuse large cell lymphoma (DLCL) treatment outcomes require improvement.
Understanding failures of prior therapies is crucial for developing new strategies.

Purpose of the Study:

To explore novel therapeutic strategies for DLCL.
To develop testable hypotheses for improving lymphoma treatment.

Main Methods:

Utilizing the International Non-Hodgkin's Lymphoma Prognostic Factors Index for patient cohort comparison.
Investigating new drug identification and dose escalation with colony-stimulating factors.
Exploring strategies to overcome chemotherapy resistance and combining monoclonal antibodies with chemotherapy.
Evaluating ablative chemotherapy with autologous stem-cell support.

Related Experiment Videos

Main Results:

Current research areas include identifying new active drugs for lymphoma.
Investigating dose escalation of myelotoxic drugs using colony-stimulating factors.
Developing strategies to overcome chemotherapy resistance and combining monoclonal antibodies with chemotherapy.
Assessing ablative chemotherapy with autologous stem-cell support.

Conclusions:

A hypothesis suggests high-risk aggressive lymphoma patients benefit from high-dose therapy after standard induction.
A clinical trial is planned to test this hypothesis for improved treatment outcomes.